- Home
- KIO vs UPB Comparison
KIO vs UPB Comparison
Compare KIO & UPB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KIO
- UPB
- Stock Information
- Founded
- KIO 2011
- UPB 2021
- Country
- KIO United States
- UPB United States
- Employees
- KIO 2400
- UPB N/A
- Industry
- KIO Investment Managers
- UPB
- Sector
- KIO Finance
- UPB
- Exchange
- KIO Nasdaq
- UPB NYSE
- Market Cap
- KIO 514.6M
- UPB 521.3M
- IPO Year
- KIO N/A
- UPB 2024
- Fundamental
- Price
- KIO $12.73
- UPB $15.54
- Analyst Decision
- KIO
- UPB Strong Buy
- Analyst Count
- KIO 0
- UPB 4
- Target Price
- KIO N/A
- UPB $56.50
- AVG Volume (30 Days)
- KIO 136.5K
- UPB 434.2K
- Earning Date
- KIO 01-01-0001
- UPB 08-14-2025
- Dividend Yield
- KIO 10.82%
- UPB N/A
- EPS Growth
- KIO N/A
- UPB N/A
- EPS
- KIO N/A
- UPB N/A
- Revenue
- KIO N/A
- UPB $2,296,000.00
- Revenue This Year
- KIO N/A
- UPB N/A
- Revenue Next Year
- KIO N/A
- UPB N/A
- P/E Ratio
- KIO N/A
- UPB N/A
- Revenue Growth
- KIO N/A
- UPB N/A
- 52 Week Low
- KIO $10.52
- UPB $5.14
- 52 Week High
- KIO $13.59
- UPB $29.46
- Technical
- Relative Strength Index (RSI)
- KIO 64.63
- UPB N/A
- Support Level
- KIO $12.54
- UPB N/A
- Resistance Level
- KIO $12.81
- UPB N/A
- Average True Range (ATR)
- KIO 0.09
- UPB 0.00
- MACD
- KIO 0.00
- UPB 0.00
- Stochastic Oscillator
- KIO 77.78
- UPB 0.00
About KIO KKR Income Opportunities Fund
KKR Income Opportunities Fund operates as a closed-end registered management investment company. It seeks to generate a high level of current income, with a secondary objective of capital appreciation. The company invests in the portfolio of loans and fixed-income instruments of U.S. and non-U.S. issuers. The company will invest at least 80% of its Managed Assets in loans and fixed-income instruments or other instruments, including derivative instruments, with similar economic characteristics under normal market conditions.
About UPB UPSTREAM BIO INC
Upstream Bio Inc is a clinical-stage biotechnology company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders. It is developing verekitug, the known antagonist currently in clinical development that targets the receptor for Thymic Stromal Lymphopoietin (TSLP), a cytokine that is a clinically validated driver of inflammatory response positioned upstream of multiple signaling cascades that affect a variety of immune-mediated diseases.